Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load.

Emma H.A. Stahlie,Viola Franke,Charlotte L. Zuur,W.M.C. Klop,Bernies van der Hiel,Bart A. van de Wiel,Michel W.J.M. Wouters,Yvonne Schrage,Winan J. van Houdt,Alexander C.J. van Akkooi

Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load.

2020

Emma H.A. Stahlie
Viola Franke
Charlotte L. Zuur
W.M.C. Klop
Bernies van der Hiel
Bart A. van de Wiel
Michel W.J.M. Wouters
Yvonne Schrage
Winan J. van Houdt
Alexander C.J. van Akkooi

e22089Background: Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus, which is used as an oncolytic immunotherapy in stage IIIB-IVM1a melanoma patients. It is kn...

Keywords:

stage iiib
Internal medicine
Oncology
Talimogene laherparepvec
Melanoma
Tumor Load
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations